Home >   Products   >  Advanced Search

Warfarin Sodium (contains Isopropyl Alcohol)
(CAS RN:129-06-6 Product Number:W0005)

Structure

Warfarin Sodium
Synonym 3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol)
Synonym 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol)

General Information

Product Number W0005

* Items available from stock in Japan will be delivered in 10 business days.
* Please contact us if you need further information.
(Sales Dept Tel: +32 (0)3 735 07 00 E-mail: Sales-EU@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that for some of our products we cannot offer bulk quantities.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >98.0%(HPLC)
Storage Temperature
M.F. / M.W. C19H15NaO4=330.31
CAS RN 129-06-6
Related CAS RN 81-81-2
MDL Number MFCD00083223
Packaging and Container
  • Product Details
  • Safety & Regulations

Specification

Purity(HPLC) min. 98.0 area%
Purity(Nonaqueous Titration) min. 91.0 %
2-Propanol 7.0 to 9.0 %

References

Reaxys-RN 5469050
PubChem SID 87560363
Merck Index(14) 10038
RTECS# GN4725000
EC Number 204-929-4

GHS

Pictogram
Signal Word Danger
Hazard Statements
  • H300
  • :Fatal if swallowed.
  • H360FD
  • :May damage fertility. May damage the unborn child.
  • H370
  • :Causes damage to Blood (System), Kidney, Central Nervous System.
  • H372
  • :Causes damage to Blood (System), Bone, Skin through prolonged or repeated exposure.
  • H373
  • :May cause damage to Liver, Kidney, Spleen, Blood Vessels through prolonged or repeated exposure.
  • H412
  • :Harmful to aquatic life with long lasting effects.
Precautionary Statements
  • P201
  • :Obtain special instructions before use.
  • P260
  • :Do not breathe dust, fume, mist, vapours or spray.
  • P270
  • :Do not eat, drink or smoke when using this product.
  • P280
  • :Wear protective gloves, protective clothing, face protection.
  • P301+P310+P330
  • :IF SWALLOWED: Immediately call a POISON CENTER or doctor. Rinse mouth.
  • P308+P311
  • :If exposed or concerned: Call a POISON CENTER or doctor.

Transport Information

UN Number 1544
Class 6.1
Packing Group II
HS Number 2932209090

Application

Warfarin Sodium (contains Isopropyl Alcohol) Binding of Warfarin to Human Serum Albumin

Warfarin is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site I on HSA. Those were confirmed using our warfarin sodium with Surface Plasmon Resonance (SPR) and a method using fluorescent probes.
【SPR】
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.

W0005

<Assay condition>
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.

<Result>
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.

【Method using fluorescent probes】
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.

W0005

<Assay condition>
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 μM (DNSA), 20 μM (DNSG, BD140) (50 μL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 μL/well); DNSA: 80 μM, DNSG: 20 μM, BD140: 20 μM (50 μL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).

<Result>
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.

In these ways, our warfarin can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.

References

Reviews of Pharmacology of Warfarin

References

PubMed Literature

Page Top